ArticleJournal of ovarian research2025
Identification of ferroptosis- and mitochondrial metabolism-related biomarkers and the potential molecular mechanisms of poor ovarian response.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanisms of mitochondrial dysfunction in premature ovarian insufficiency.Journal of ovarian research · 2026Review
- Dicaffeoylquinic acid alleviates alcoholic liver disease by targeting PLA2G4B and inhibiting the MAPK signaling pathway.Frontiers in pharmacology · 2026Article
- Multi-omics Mendelian randomization identifies mitochondrial genes associated with immune microenvironment signatures in endometriosis.Frontiers in reproductive health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFerroptosis and mitochondrial metabolism are closely associated with the pathological processes of various diseases. However, the role of ferroptosis-related genes (FRGs) and mitochondrial metabolism-related genes (MMRGs) in poor ovarian response (POR) remains unexplored.
methodsFirst, transcriptome sequencing was conducted on ovarian granulosa cell samples from POR patients and controls. Candidate genes were screened through differential expression analysis and consensus clustering analysis. The biomarkers were subsequently screened using machine learning algorithms and receiver operating characteristic (ROC) curves. Nomogram construction and evaluation, enrichment analysis, drug prediction analysis, and molecular docking were subsequently carried out using the biomarkers. Finally, the expression of the biomarkers was authenticated using reverse transcription‒quantitative polymerase chain reaction (RT‒qPCR).
resultsPLA2G4B and PRKCG were identified as biomarkers by screening. The nomogram demonstrated that these two biomarkers could effectively predict the occurrence of POR. Gene set enrichment analysis (GSEA) revealed that PLA2G4B and PRKCG were both associated with terpenoid backbone biosynthesis. A TF-miRNA-mRNA network was constructed using the biomarkers. For PLA2G4B, dirithromycin had the highest score among the targeted drugs, whereas for PRKCG, bryostatins and enzastaurin had the highest scores. Molecular docking results indicated that their binding energies were less than - 5 kcal/mol. RT‒qPCR revealed that PLA2G4B and PRKCG were significantly upregulated in POR samples, which was consistent with the high-throughput sequencing results.
conclusionPLA2G4B and PRKCG have been identified as potential mitochondrial- and ferroptosis-related biomarkers in POR, providing valuable insights for exploring the pathogenesis of POR. These findings may also aid in the development of new diagnostic and therapeutic strategies for POR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.